354 related articles for article (PubMed ID: 12823574)
1. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients.
Doose DR; Brodie MJ; Wilson EA; Chadwick D; Oxbury J; Berry DJ; Schwabe S; Bialer M
Epilepsia; 2003 Jul; 44(7):917-22. PubMed ID: 12823574
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy.
Rosenfeld WE; Liao S; Kramer LD; Anderson G; Palmer M; Levy RH; Nayak RK
Epilepsia; 1997 Mar; 38(3):324-33. PubMed ID: 9070595
[TBL] [Abstract][Full Text] [Related]
3. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
Sachdeo RC; Sachdeo SK; Levy RH; Streeter AJ; Bishop FE; Kunze KL; Mather GG; Roskos LK; Shen DD; Thummel KE; Trager WF; Curtin CR; Doose DR; Gisclon LG; Bialer M
Epilepsia; 2002 Jul; 43(7):691-6. PubMed ID: 12102670
[TBL] [Abstract][Full Text] [Related]
4. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy.
Sachdeo RC; Sachdeo SK; Walker SA; Kramer LD; Nayak RK; Doose DR
Epilepsia; 1996 Aug; 37(8):774-80. PubMed ID: 8764818
[TBL] [Abstract][Full Text] [Related]
5. Lack of an effect of topiramate on lamotrigine serum concentrations.
Berry DJ; Besag FM; Pool F; Natarajan J; Doose D
Epilepsia; 2002 Aug; 43(8):818-23. PubMed ID: 12180999
[TBL] [Abstract][Full Text] [Related]
6. Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy.
Levy RH; Ragueneau-Majlessi I; Brodie MJ; Smith DF; Shah J; Pan WJ
Ther Drug Monit; 2005 Apr; 27(2):193-8. PubMed ID: 15795651
[TBL] [Abstract][Full Text] [Related]
7. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.
Bialer M; Shekh-Ahmad T; Braun TL; Halvorsen MB
Epilepsia; 2013 Aug; 54(8):1444-52. PubMed ID: 23692553
[TBL] [Abstract][Full Text] [Related]
8. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
Tompson DJ; Ali I; Oliver-Willwong R; Job S; Zhu L; Lemme F; Hammer AE; Vuong A; Messenheimer JA
Epilepsia; 2008 Mar; 49(3):410-7. PubMed ID: 17825077
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units.
Lardizabal DV; Morris HH; Hovinga CA; Del Mar Carreño M
Epilepsia; 2003 Apr; 44(4):536-9. PubMed ID: 12681002
[TBL] [Abstract][Full Text] [Related]
10. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Meador KJ; Loring DW; Vahle VJ; Ray PG; Werz MA; Fessler AJ; Ogrocki P; Schoenberg MR; Miller JM; Kustra RP
Neurology; 2005 Jun; 64(12):2108-14. PubMed ID: 15985582
[TBL] [Abstract][Full Text] [Related]
11. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis.
Luszczki JJ; Czuczwar M; Kis J; Krysa J; Pasztelan I; Swiader M; Czuczwar SJ
Epilepsia; 2003 Aug; 44(8):1003-13. PubMed ID: 12887431
[TBL] [Abstract][Full Text] [Related]
12. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy.
Lhatoo SD; Wong IC; Polizzi G; Sander JW
Epilepsia; 2000 Dec; 41(12):1592-6. PubMed ID: 11114218
[TBL] [Abstract][Full Text] [Related]
13. Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study.
Matsuo F; Gay P; Madsen J; Tolman KG; Rollins DE; Risner ME; Lai AA
Epilepsia; 1996 Sep; 37(9):857-62. PubMed ID: 8814098
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations.
Brittain ST; Wheless JW
Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125
[TBL] [Abstract][Full Text] [Related]
15. An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy.
Baldoni AO; Freitas-Lima P; de Santi Ferreira FI; Martinez EZ; Queiroz RH; Sakamoto AC; Alexandre V; Perucca E; Pereira LR
Clin Exp Pharmacol Physiol; 2016 Jul; 43(7):685-9. PubMed ID: 27120710
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J
Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542
[TBL] [Abstract][Full Text] [Related]
17. The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting.
Helmstaedter C; Witt JA
Epilepsy Behav; 2013 Feb; 26(2):182-7. PubMed ID: 23318473
[TBL] [Abstract][Full Text] [Related]
18. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Contin M; Riva R; Albani F; Avoni P; Baruzzi A
Ther Drug Monit; 2002 Jun; 24(3):332-7. PubMed ID: 12021622
[TBL] [Abstract][Full Text] [Related]
19. Preliminary observations on topiramate in pediatric epilepsies.
Glauser TA
Epilepsia; 1997; 38 Suppl 1():S37-41. PubMed ID: 9092958
[TBL] [Abstract][Full Text] [Related]
20. Interaction between anticonvulsants and human placental carnitine transporter.
Wu SP; Shyu MK; Liou HH; Gau CS; Lin CJ
Epilepsia; 2004 Mar; 45(3):204-10. PubMed ID: 15009220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
